Literature DB >> 15650059

Identification of a human B-cell/myeloid common progenitor by the absence of CXCR4.

Yong-Hao Hou1, Edward F Srour, Heather Ramsey, Richard Dahl, Hal E Broxmeyer, Robert Hromas.   

Abstract

CXCR4 is a chemokine receptor required for hematopoietic stem cell engraftment and B-cell development. This study found that a small fraction of primitive CD34(+)/CD19(+) B-cell progenitors do not express CXCR4. These CD34(+)/CD19(+)/CXCR4(-) cells were also remarkable for the relative lack of primitive myeloid or lymphoid surface markers. When placed in B-lymphocyte culture conditions these cells matured to express CXCR4 and other surface antigens characteristic of B cells. Surprisingly, when placed in a myeloid culture environment, the CXCR4(-) B-cell progenitors could differentiate into granulocyte, macrophage, and erythroid cells at a high frequency. These data define a novel B-cell/myeloid common progenitor (termed the BMP) and imply a less restrictive pathway of myeloid versus lymphoid development than previously postulated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650059      PMCID: PMC1895023          DOI: 10.1182/blood-2004-07-2839

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Stepwise lineage restriction of progenitors in lympho-myelopoiesis.

Authors:  Y Katsura; H Kawamoto
Journal:  Int Rev Immunol       Date:  2001-02       Impact factor: 5.311

Review 2.  Fidelity and infidelity in commitment to B-lymphocyte lineage development.

Authors:  A G Rolink; C Schaniel; M Busslinger; S L Nutt; F Melchers
Journal:  Immunol Rev       Date:  2000-06       Impact factor: 12.988

Review 3.  Haematopoietic stem cells.

Authors:  Dominique Bonnet
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

Review 4.  Lymphoid precursors.

Authors:  K Akashi; T Reya; D Dalma-Weiszhausz; I L Weissman
Journal:  Curr Opin Immunol       Date:  2000-04       Impact factor: 7.486

5.  SDF-1 responsiveness does not correlate with CXCR4 expression levels of developing human bone marrow B cells.

Authors:  M Honczarenko; R S Douglas; C Mathias; B Lee; M Z Ratajczak; L E Silberstein
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

6.  Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines.

Authors:  M J Robertson; B T Williams; K Christopherson; Z Brahmi; R Hromas
Journal:  Cell Immunol       Date:  2000-01-10       Impact factor: 4.868

7.  Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4.

Authors:  K E McGrath; A D Koniski; K M Maltby; J K McGann; J Palis
Journal:  Dev Biol       Date:  1999-09-15       Impact factor: 3.582

8.  The human hematopoietic stem cell compartment is heterogeneous for CXCR4 expression.

Authors:  M Rosu-Myles; L Gallacher; B Murdoch; D A Hess; M Keeney; D Kelvin; L Dale; S S Ferguson; D Wu; F Fellows; M Bhatia
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

9.  Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines.

Authors:  M Kondo; D C Scherer; T Miyamoto; A G King; K Akashi; K Sugamura; I L Weissman
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

10.  Human CD34(+)CXCR4(-) sorted cells harbor intracellular CXCR4, which can be functionally expressed and provide NOD/SCID repopulation.

Authors:  Orit Kollet; Isabelle Petit; Joy Kahn; Sarit Samira; Ayelet Dar; Amnon Peled; Varda Deutsch; Monica Gunetti; Wanda Piacibello; Arnon Nagler; Tsvee Lapidot
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

View more
  8 in total

1.  A Case of Acute Myeloid Leukemia Concurrent With Untreated Chronic Lymphocytic Leukemia.

Authors:  Hye Young Lee; Chan Jeoung Park; Enkyung You; Young Uk Cho; Seongsoo Jang; Eul Ju Seo
Journal:  Ann Lab Med       Date:  2017-07       Impact factor: 3.464

2.  Human cancers overexpress genes that are specific to a variety of normal human tissues.

Authors:  Joseph Lotem; Dvir Netanely; Eytan Domany; Leo Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

3.  The phosphatidylserine receptors, T cell immunoglobulin mucin proteins 3 and 4, are markers of histiocytic sarcoma and other histiocytic and dendritic cell neoplasms.

Authors:  David M Dorfman; Jason L Hornick; Aliakbar Shahsafaei; Gordon J Freeman
Journal:  Hum Pathol       Date:  2010-07-24       Impact factor: 3.466

4.  The density of CD10 corresponds to commitment and progression in the human B lymphoid lineage.

Authors:  Michiko Ichii; Kenji Oritani; Takafumi Yokota; Qingzhao Zhang; Karla P Garrett; Yuzuru Kanakura; Paul W Kincade
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

5.  Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone.

Authors:  Andrew L Feldman; Daniel A Arber; Stefania Pittaluga; Antonio Martinez; Jerome S Burke; Mark Raffeld; Mireia Camos; Roger Warnke; Elaine S Jaffe
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

6.  Intravascular lymphomatosis of the brain in a patient with myelodysplastic syndrome.

Authors:  Gregorius J Sips; Colum F Amory; Bradley N Delman; George M Kleinman; Lewis R Lipsey; Stanley Tuhrim
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

7.  KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma.

Authors:  Sarah M Choi; Aleodor A Andea; Min Wang; Amir Behdad; Lina Shao; Yanming Zhang; Xinyan Lu; David Dittmann; Juan Castro; Yi-Hua Chen; Juehua Gao
Journal:  Diagn Pathol       Date:  2018-10-15       Impact factor: 2.644

8.  Differentiation Epitopes Define Hematopoietic Stem Cells and Change with Cell Cycle Passage.

Authors:  Laura R Goldberg; Mark S Dooner; Elaine Papa; Mandy Pereira; Michael Del Tatto; Yan Cheng; Sicheng Wen; Peter J Quesenberry
Journal:  Stem Cell Rev Rep       Date:  2022-05-03       Impact factor: 6.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.